5 active not recruiting, 5 completed, 2 unknown, 1 not yet recruiting. 16 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Active not recruiting 5, Completed 5, Unknown 2, Not yet recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow BCG: new trials by email Literature Review of BCG trials Research Report on BCG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer. radiotherapy, BCG - High-Risk Non-Muscle Invasive Bladder Cancer | Phase 3 | Not yet recruiting | The Christie NHS Foundation Trust | 328 | 2025-12-01 | 2025-12-05 |
| Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC) BCG for Therapeutic Use - Non-Muscle Invasive Bladder Cancer | Phase 3 | Unknown | Chengdu CoenBiotech Co., Ltd | 412 | 2023-12-28 | 2024-02-05 |
| BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants Durvalumab, BCG - Non-Muscle- Invasive Bladder Cancer | Phase 3 | Active not recruiting | AstraZeneca | 100 | 2023-08-11 | 2026-08-13 |
| Intravesical BCG vs GEMDOCE in NMIBC Gemcitabine, Docetaxel, Bacillus Calmette Guerin - Non-muscle-invasive Bladder Cancer | Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 870 | 2023-02-07 | 2026-09-15 |
| Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa MTBVAC, BCG - Tuberculosis | Phase 3 | Recruiting | Biofabri, S.L | 7120 | 2022-10-17 | 2025-02-10 |
| Immunological Response of Bladder Cancer Patients Under BCG Bacillus Calmette Guerin, PLACEBO - Bladder Cancer, Bacillus Calmette-Guerin | Phase 3 | Completed | University of Campinas, Brazil | 30 | 2021-09-03 | 2024-12-09 |
| A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer PF-06801591, Bacillus Calmette-Guerin - Non-muscle Invasive Bladder Cancer | Phase 3 | Active not recruiting | Pfizer | 1068 | 2019-12-30 | 2026-10-15 |
| Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients BCG, Atezolizumab - Bladder Cancer | Phase 3 | Active not recruiting | UNICANCER | 517 | 2019-01-17 | 2024-12-11 |
| Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) Pembrolizumab, BCG - High-risk Non-muscle Invasive Bladder Cancer | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 1397 | 2018-12-24 | 2026-10-23 |
| Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer BCG instillation therapy, Sequential BCG and EMDA mitomycin C - Bladder Cancer | Phase 3 | Unknown | Turku University Hospital | 300 | 2018-10-26 | 2021-04-01 |
| Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65(III-healthy) Bacillus Calmette - Guerin, placebo of Bacillus Calmette - Guerin - Tuberculosis | Phase 3 | Completed | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 1802 | 2016-05-01 | 2020-10-01 |
| Effects of BCG on Influenza Induced Immune Response Placebo, BCG - Influenza Virus Infection, Trained Immunity | Phase 2 / Phase 3 | Completed | Radboud University Medical Center | 40 | 2014-05-01 | 2015-11-10 |
| Melbourne Infant Study - Bacille Calmette Guérin (BCG) for Allergy & Infection Reduction BCG - Allergy, Eczema | Phase 3 | Completed | Murdoch Childrens Research Institute | 1272 | 2013-07-01 | 2025-02-17 |
| Bacillus Calmette-Guerin (BCG) Vaccine and Morbidity From Malaria BCG - Malaria | Phase 3 | Completed | London School of Hygiene and Tropical Medicine | 1200 | 2003-01-01 | 2016-09-02 |
| Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer Synergo + MMC, Bacillus Calmette-Guérin - Urinary Bladder Diseases, Urinary Bladder Neoplasms | Phase 3 | Terminated | Medical Enterprises Europe B.V. | 190 | 2002-02-01 | 2014-10-07 |
| SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I Synergo + MMC, Bacillus Calmette-Guérin - Urinary Bladder Neoplasms, Urologic Neoplasms | Phase 3 | Withdrawn | Medical Enterprises Europe B.V. | 2015-04-01 |
Non-Muscle Invasive Bladder Neoplasms (7) · Urinary Bladder Neoplasms (7) · Neoplasms (2) · Neoplasms by Site (2) · Tuberculosis (2) · Urinary Bladder Diseases (2) · Urologic Diseases (2) · Urologic Neoplasms (2) · Eczema (1) · Hypersensitivity (1) · Hyperthermia (1) · Infections (1) · Influenza, Human (1) · Malaria (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1)
Medical Enterprises Europe B.V. (2) · Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (1) · AstraZeneca (1) · Biofabri, S.L (1) · Chengdu CoenBiotech Co., Ltd (1) · ECOG-ACRIN Cancer Research Group (1) · London School of Hygiene and Tropical Medicine (1) · Merck Sharp & Dohme LLC (1) · Murdoch Childrens Research Institute (1) · Pfizer (1) · Radboud University Medical Center (1) · The Christie NHS Foundation Trust (1) · Turku University Hospital (1) · UNICANCER (1) · University of Campinas, Brazil (1)
United States (4) · Australia (3) · Belgium (3) · China (3) · France (3) · Italy (3) · Netherlands (3) · Spain (3) · United Kingdom (3) · Austria (2) · Brazil (2) · Canada (2) · Finland (2) · Germany (2) · Japan (2)
Alfred A Witjes, MD PhD (1) · Amabelia Rodrigues, PhD (1) · Gerson Luedecke, Dr. med. (1) · Igal Ruvinsky, PhD (1) · Leonardo O Reis, MD, PhD (1) · Mark Hatherill (1) · Mihai Netea, PhD (1) · Morgan Roupret, MD-PHD (1) · Prof Nigel Curtis, MBBS DCH DTM&H MRCP FRCPCH PhD (1) · Wei Lu, Master (1) · Yohann Loriot, MD (1)
PMID 16389183, PMID 26803476, PMID 26845426, PMID 30791143, PMID 31843845, PMID 32162533, PMID 32544459, PMID 34309859, PMID 35170523, PMID 37400353, PMID 38189180, PMID 39004434, PMID 39752894, PMID 40450141, PMID 40464744, PMID 41047269, PMID 41436847, PMID 42177753, PMID 42605566
2017 (1), 2018 (1), 2023 (1), U10CA180820 (1)